

and providing instructions for the prophylactic or therapeutic use of said immunogens to reduce the incidence or severity of a chronic immune-mediated disorder in a mammal, said instructions stating that one or more doses should be administered according to an immunization schedule set forth in said instructions, said immunogens, when so administered, acting to substantially reduce the incidence or severity of said chronic immune-mediated disorder,

or

F2  
42  
(b) that at least one immunogen of the kit, [depending on] when [one or more of said immunogens is] administered according to one or more immunization schedules, may, can or does, or has been reported to, increase the incidence or accelerate the onset of a chronic immune-mediated disorder, or

(c) regarding any animal study or clinical study of the effect of any of said immunogens, or of any immunization schedule for any of said immunogens, on the incidence of a chronic immune-mediated disorder, or on the time of onset of said disorder.

F3  
64 (amended). The kit of claim 59 wherein following such instructions the first administration is at a time from birth to [when the mammal is] about 7 days [old] after birth.

F4  
96 (amended). The kit of claim 61 wherein the labeling indicates that the kit, depending on [when] the immunization schedule according to which one or more of said immunogens is administered, can or does increase the incidence or accelerate the onset of said disorder.

97 (amended). The kit of claim 61 wherein the labeling indicates that the kit, depending on [when] the immunization schedule according to which one or more of said immunogens is administered, may, can or does increase the incidence of said

disorder.

78. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is an immune mediated cancer and where said mammal is human.

79. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is an autoimmune disease and where said mammal is human.

80. The kit of claim 79 in which the disease is a rheumatic disease or connective tissue disease and where said mammal is human.

81. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is a neurological disease and where said mammal is human.

82. The kit of claim 81 in which the disease is multiple sclerosis and where said mammal is human.

83. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, , 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is [a chronic] asthma [or chronic allergy] and where said mammal is human.

84. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is non-streptozotocin-induced diabetes and where said mammal is human.

85. The kit [of claim 59] any of claims 59, 60, 61, 62, 96 97, 30, 49, 55, 74, 76, 77, 89-92, 98-100, 106, 114-17, 125 or 126 in which the disorder is systemic lupus [erythematosus] erythematosus and where said mammal is human.

In claim 5, line 3, delete "and"; line 5, replace "and" with --or--.

In claims 19, 70, and 76 insert a comma between "dengue" and

USSN - 08/591,651

"toxoplasmosis".

In claims 29, 36, 37, 39, 50, 51, 66, 68, 70 and 71, replace "27" with --43--.

In claim 30, line 2, delete "a", line 4, replace "immunogen" with --immunogens--.

In claims 30, 49, 55, 72, 74, 76, 77, 89-92 and 98-100, replace "59" with --16--.

In claim 35, line 3, replace "erythrematosis" with --erythematosus--.

In claim 37, line 5, replace "and" with --or--; line 6, delete "is administered".

In claim 43, replace "27" with --28--.

In claims 71 and 77, line 3, replace "or" with --and--, line 4, replace "immunogen" with --immunogens--.

Please cancel claims 15, 26, 48 and 58.

Please add the following new claims:

*Rule 120*  
~~106~~ 106. The kit of claim 16 where said labeling indicates that humans with a family history of a chronic immune-mediated disorder may be at increased risk for developing that disorder after immunization.

~~110~~ 107. The kit of claim 16 in which every immunogen is provided other than by a live vaccine.

~~111~~ 108. The kit of claim 72 in which every immunogen is provided other than by a live vaccine.

*FS*  
~~112~~ 109. The kit of claim 74 in which every immunogen is provided other than by a live vaccine.

~~113~~ 110. The kit of claim 75 in which every immunogen is provided other than by a live vaccine.

~~114~~ 111. The kit of claim 76 in which every immunogen is provided other than by a live vaccine.

~~115~~ 112. The kit of claim 77 in which every immunogen is provided other than by a live vaccine.

~~116~~ 113. The kit of claim 16 which is for use to protect

against at least two different infectious diseases, and provides at least one immunogen protecting against each of said diseases.

~~117~~<sup>117</sup>~~114~~. The kit of claim 16 which comprises both at least one pediatric immunogen and at least one non-pediatric immunogen.

~~118~~<sup>118</sup>~~115~~. The kit of claim 16 where said instructions provide for administering the first dose of at least one immunogen on or after 42 days after birth.

~~119~~<sup>119</sup>~~116~~. The kit of claim 16 wherein, according to said instructions, the first administration when the mammal is less than 28 days old.

~~120~~<sup>120</sup>~~117~~. The kit of claim 16 wherein, according to said instructions, the first administration when the mammal is less than 42 days old.

~~121~~<sup>121</sup>~~118~~. The kit of claim 30 where at least one immunogen is selected from the group consisting of a diphtheria, tetanus, polio, hepatitis B and hemophilus influenza B immunogens.

~~122~~<sup>122</sup>~~119~~. The kit of any of claims 66, 67, 68, 69, 70 or 71 in which every immunogen is provided other than by a live vaccine.

~~123~~<sup>123</sup>~~120~~. The kit of claim 43 wherein said kit contains at least one immunogen selected from the group consisting of a diphtheria, tetanus, polio, Hepatitis B, Hemophilus influenza b, pertussis, and BCG immunogen.

~~124~~<sup>124</sup>~~121~~. The kit of claim 43 wherein said kit contains at least one immunogen selected from the group consisting of diphtheria, tetanus, polio, Hepatitis B, and Hemophilus influenza b immunogens.

~~125~~<sup>125</sup>~~122~~. The kit of claim 43 which is for use to protect against at least two different infectious diseases, and providing at least one immunogen protecting against each of said diseases.

~~126~~<sup>126</sup>~~123~~. The kit of claim 43 which comprises both at least one pediatric immunogen and at least one non-pediatric immunogen.

~~127~~<sup>127</sup>~~124~~. The kit of any of claims 59, 60, 61, 62, 96, 97, 30, 49, 55, 74, 76, 77, 89, 91, 92, 98-100, or 106-117 in which the

disorder is one which develops at least one year after a vaccination.

*128 125*  
A method of reducing the risk of a chronic immune-mediated disorder associated with immunization to protect against an infectious disease, comprising (1) determining the occurrence of at least one chronic immune mediated disorder in humans occurring during at least a one year time span after administering an immunogen according to one or more immunization schedules or determining the effect of timing of administering an immunogen on the development of a chronic immune mediated disorder, and (2) providing a kit according to claim 59 comprising at least one of said immunogens and labeling, said labeling indicating that one or more doses of said immunogen can be administered according to more than one immunization schedule or at more than one age set forth in said instructions, said immunogens, when so administered, acting to substantially protect against at least one infectious disease,

*Full 126*  
*FS*  
*WV*

where administration according to different immunization schedules may have different effects on the incidence of said chronic immune mediated disorder;

and adhering to said warnings in said instructions may lead to a lower incidence of said chronic immune mediated disorder.

*129 126*  
~~In a method of protecting against an infectious disease which comprises providing a vaccine kit according to claim 59 comprising one or more immunogens protective against said disease, and instructions setting forth at least one immunization schedule for administering said immunogens, which, if followed, results in protection against such disease, said instructions stating that one or more immunogens can be administered according to more than one immunization schedule~~

~~and warning that administration according to different immunization schedules may have different effects on the incidence of a chronic immune mediated disorder;~~

so that adhering to said warnings in said instructions may lead to a lower incidence of said chronic immune mediated disorder.

*130 127* 127. In a method of vaccine packaging, wherein a vaccine is packaged with labeling providing directions for use, adequate warnings against unsafe dosage or methods or duration of administration, and information relating to side effects or to possible dangers to health when used as prescribed, recommended or suggested in the labeling, the improvement comprising: said labeling indicating that said vaccine may, can or has been reported to affect the incidence, in humans to whom it is administered, of a chronic immune mediated disorder.

*131 128* 128. The method of claim 127 where said labeling indicates that the timing of the first administration of said vaccine may, can or has been reported to affect said incidence.

*132 129* 129. The method of claim 128 where said labeling indicates that first administration of said vaccine before 42 days after birth may, can or has been reported to reduce the incidence.

*133 130* 130. The method of claim 127 where said labeling indicates that first administration of said vaccine on or after 42 days after birth may, can or has been reported to increase the incidence.

*134 131* 131. The method of claim 129 where said directions call for first administration before 42 days after birth.

*135 132* 132. The method of claim 130 where said package indicates individuals who have a mother, father or close relative with a chronic immune mediated disorder may be at risk for developing said chronic immune mediated disorder.

*136 133* 133. The method of claim 132 where said chronic immune mediated disorder is diabetes.

*137 134* 134. A method of human vaccine development and production which comprises

(a) screening a human vaccine for its effect, during